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ABSTRACT
DNase I hypersensitive site 2 (HS 2) of the human ,B-
globin Locus Control Region (LCR) directs high level
expression of the f-globin gene located 50 kilobases
downstream. Experiments in cultured cells and in
transgenic mice demonstrate that duplicated APl -like
sites in HS 2 are required for this powerful enhancer
activity. A cDNA clone encoding a basic, leucine-zipper
protein that binds to these sites was isolated and
designated Locus Control Region-Factor 1 (LCR-F1).
This protein is a member of a new family of regulatory
factors that contain a 63 amino acid 'CNC domain'
overlapping the basic region. This domain is
approximately 70% identical in the Drosophila Cap N
Collar (CNC) protein, NF-E2 and LCR-F1. LCR-F1
transactivates an HS 2/y-globin reporter gene over
170-fold in transient transfection experiments
specifically in erythroid cells. These results suggest
that LCR-F1 may be a critical factor involved in LCR-
mediated, human globin gene expression.
INTRODUCTION
The human (-globin Locus Control Region (LCR) is a 16 kilobase
region ofDNA located 6 to 22 kilobases upstream of the e-globin
gene (Figure 1). Five DNase I hypersensitive sites have been
mapped in this area and four of these sites (5' HS 1 -4) are
erythroid-specific and developmentally stable; that is, they are
present in erythroid cells at all stages of development (1-3).
The functional significance of these sequences has been
demonstrated in numerous experiments in which the sites are
linked to e-, -y- and/or 3-globin genes and expression is assayed
in transgenic mice or in cultured erythroid cells [for reviews see
(4-7) ]. In transgenic mice 5' HS 1-5 sites enhance the
expression of a linked j-globin gene 300-fold (8, 9). Individual
sites 5' HS 2, 5' HS 3 and 5' HS 4 activate expression
approximately 100 fold in transgenic animals and 5' HS 1 lacks
significant activity (9-13); the 5' HS 5 site may contain a domain
boundry sequence that insulates globin gene family members from
effects of upstream regions (14). The importance of sites 5' HS
GenBank accession no. U08853
2-4 has been confirmed by deletion of these sequences in an
Hispanic 3-thalassemia patient. This deletion results in the
absence of E-, y-, and ,B-globin expression from the mutant
chromosome even though all gene family members are intact (15).
Furthermore, Forrester et al. (16) have demonstrated that the
entire 3-globin locus in this patient, including a region of DNA
located 100 kb downstream of the ,B-globin gene, is resistant to
DNase I digestion in erythroid cells. These results suggest that
the LCR has 2 important activities. First, the sequences 'open'
a 200 kb (-globin chromosomal domain specifically in erythroid
cells and secondly, they serve as a master enhancer for e-, y-,
and 3-globin gene expression.
To define the sequences responsible for these activities we and
others footprinted nuclear proteins from erythroid and non-
erythroid cells on DNA fragments containing 5' HS 2. Individual
factor binding sites were then deleted and the mutant HS 2 ,B-
globin constructs were tested in erythroid culture cells (17-19)
or in transgenic mice (20-22). Deletion of duplicated API-like
sites in 5' HS 2 virtually eliminated enhancer activity. These
results demonstrated the functional significance of the API-like
sites and suggested that proteins which bind to the sites are critical
for human ,3-globin gene expression.
Two functional assays suggest that API is not responsible for
the activity of these sites. First, overexpression of c-Jun in the
human erythroleukemia cell line K562 does not activate but
significantly inhibits globin gene expression (18). Secondly, a
G to T transversion located 2 bp upstream of the AP1 consensus
sequence in 5' HS 2 (Figure 1) does not inhibit API binding in
vitro but severely inhibits expression of HS 2 3-globin gene
constructs in erythroid cells (17-19). These data suggest that
proteins other than API bind to the APi-like sites in 5' HS 2
and activate high levels of globin gene expression.
MATERIALS AND METHODS
Transgenic animal experiments
The 5' HS2 (K-P) ,B fragments were purified from plasmid
sequences and analyzed in mice as described (21). Human and
mouse 3-globin levels in 16-day fetal livers were determined by
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primer extension and by solution hybridization with human and
mouse (-globin oligonucleotides (9, 23). The fraction of
expressors represents the number of transgenic animals that
express the transgene. Expression/gene copy is the mean percent
expression per gene copy; this value is calculated as follows:
(human ( mRNA/human ( gene copy)/(mouse ( mRNA/ mouse
( gene copy) x 100. Site-specific mutations in 5' HS 2 (K-P)
,3 were made in the pSELECT system as described by the
manufacturer (Promega). The mutagenic oligonucleotides were
as follows:
G >T 5' CAAGCACAGCAATTCTGAGTCATTATGAGTCATGCTGAGGC 3'
A>C 5' CAAGCACAGCAATGCTGCGTCATGATGCGTCATGCTGAGGC 3'
Construction and screening of K562 cDNA library
Poly A RNA was purified from uninduced K562 cells and double-
stranded cDNA was prepared with the Superscript cDNA kit from
Bethesda Research Labs (BRL) as described by the supplier.
EcoRI-NotI adaptors (BRL) were ligated onto the termini.
cDNAs larger than 500 bps were purified on a Sephacryl S-500
HR column (BRL) and ligated with EcoRI digested,
dephosphorylated Xgtl 1 arms (BRL). DNA was packaged
(Packagene, Promega) and 5 x 105 phage were plated onto
Y1090 cells at 20,000 phage/15 cm plate. The plaques were
blotted onto nitrocellulose and probed with multimerized 5' HS2
API-like sites as described (24, 25). The double stranded
oligonucleotides were as follows:
API 5' ATGCTGAGTCATGATGAGTCATGCTGAGGCTTAGGG 3'
3' ACTCAGTACTACTCAGTACGACTCCGAATCCCTACG 5'
G >T 5' ATTCTGAGTCATTATGAGTCATGCTGAGGCTTAGGG 3'
3' ACTCAGTAATACTCAGTACGACTCCGAACCCTAAG 5'
A>C 5' ATGCTGCGTCATGATGCGTCATGCTGAGGCTTAGGG 3'
3' ACGCAGTACTACGCAGTACGACTCCGAATCCCTACG 5'
C/EBP 5' AATTCAATTGGGCAATCAGG 3'
3' GTrAACCCGTrAGTCCTTAA 5'.
The 4 bp sequences at the 5' ends of the oligonucleotides are
complementary to allow the formation of head to tail
concatomers. The two strands were annealed and the double
stranded oligonucleotides were ligated to form multimers.
Multimers of 150-300 base pairs were purified on agarose gels
and labeled by nick translation (26). Following the isolation and
characterization of the initial clone, a second K562 cDNA library
(Clontech) was screened with the 1.7 kb LCR-F1 insert. Clones
that overlapped the 5' and 3' ends of the original clone were
isolated and sequenced.
Northern blot hybridizations
Five or ten micrograms of total RNA from cell lines or primary
tissues were fractionated on a 1.5% agarose gel containing 1.85%
formaldehyde. RNA was blotted to a Duralose Membrane
(Stratagene), UV crosslinked in a Stratagene Stratalinker
(autosetting) and baked in vacuo at 80°C for 30 min. The blots
were probed with a randomly labeled, 0.96 kb BamHI-EcoRI
fragment containing the 3' end of the LCR-Fl cDNA.
Gel shift analysis
Gel shift eperiments were performed as described (27, 28).
Briefly, 20,000 cpm of 5' end-labeled oligonucleotides containing
the duplicated API-like sites from 5' HS 2 were mixed with a
100-fold molar excess of the indicated, unlabeled oligonucleotides
and incubated with 100 ng of glutathione-sepharose purified
GST/LCRF-1 for 30 minutes at 4°C in 10 mM Tris pH 7.5, 50
mM NaCl, 5 mM MgCl2, 1 mM EDTA, 1 mM DTT, and 5%
glycerol. Products were resolved on 4% nondenaturing
polyacrylamide gels in 0.5 x TBE. Oligonucleotides used for














HS2 (AP1x2) -y/Luc, HS2 (APlx2) tk/Luc, HS2 (Gal4x2) y/Luc
and HS2 (Gal4x2) tk/Luc reporter plasmids were constructed as
follows. The 1.5 kb KpnI -BglII fragment of 5' HS 2 was
inserted into KpnI -BglII digested pGL2-Basic (Promega) to
produce a plasmid designated HS2 (AP1x2) Luc. HS2 (Gal4x2)
Luc was constructed by replacing the duplicated API-like sites
in HS 2 with GAL4 binding sites using the megaprimer
mutagenesis method (29). The outside primers overlapped the
KpnI site and the BglIH sites of the 1.5 kb 5' HS 2 fragment.
The mutagenesis primer was a 66 base oligonucleotide:
5' CCTTCTGGCTCAAGCACAGCAATCCGGAGGACAGTCCTCCGGTGCTGAGGCTTA
GGGTGTGTGCCC 3'.
HS2 (APlx2) -y/Luc and HS2 (Gal4x2) y/Luc were produced
by digesting HS2 (AP1x2) Luc and HS2 (Gal4x2) Luc with BglII,
blunting the ends with Klenow fragment of DNA polymerase and
inserting a 335 bp AluI fragment containing human Ag promoter
and 5' untranslated sequence from -299 to +36. HS2 (APlx2)
tk/Luc and HS2 (Gal4x2) tk/Luc were produced by digesting HS2
(APlx2) Luc and HS2 (Gal4x2) Luc with BglII and inserting
a 140 bp BglII PCR fragment containing HSV tk promoter and
5' untranslated sequence from - 120 to +20. The - 120 to +20
tk promoter fragment with Bgl II ends was obtained by PCR
amplification using the plasmid pREP4 (Invitrogen) as a template.
The primers used were: - 120, 5' CCCGGGAGATCTATGT-
CTTTAGTTCTATGATGACAC 3'; +20,5' CCCGGGAGA-
TCTGCTGCAGGGTCGCTCGGTGTTCGA 3'. The PCR
product was digested with BglII and subcloned into BgllI digested
HS2 (APlx2) Luc and HS2 (Gal4x2) Luc.
The Gal4/LCR-F 1 expression plasmid was constructed by
inserting the 1.7 kb LCR-F1 cDNA fragment into the EcoRI site
of pBXG1 (gift of V. Seyfert and M. Ptashne). This plasmid
contains the SV40 promoter and enhancer inserted upstream of
the Gal4 DNA binding domain (amino acids 1- 147).
The Gal4/NF-E2 expression plasmid was constructed by
inserting a 1.15 kb cDNA fragment into the EcoRI site of
pBXG1. The 1.15 kb cDNA clone was obtained by RT-PCR of
Murine Erythroleukemia (MEL) cell polyA RNA using the
cDNA Cycle Kit from Invitrogen. NF-E2 cDNA was amplified
as three separate fragments which were subsequently ligated to
produce the full length clone. The primers were based on the
sequence of Andrews et al. (30) and are as follows. 5'GGATC-
CGAATTCAGTAGGATGCCCCCGTGT 3' and 5'TAAGGA-
TACTCCACTGGG 3'were used to amplify an EcoRI-NspI
fragment containing codons 1-175. 5'GGAGGAGCGAGTA-
CGTGG 3' and 5'CTGCCACCTTGTTCTTGC 3' were used to
amplify a NspI-SaII fragment containing codons 176 - 272. 5'C-
CAGCTGGCTCTAGTTCG 3' and 5'GGATCCGAATTCAG-
TGTCCACTCTCTAGACCAG 3' were used to amplify a
SalI -EcoRI fragment containing codons 273-373 plus a stop
codon. The full length clone was assembled in a four-way ligation
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with EcoRI digested plasmid and the 1.15 kb cDNA was
sequenced completely; no PCR artifacts were observed. The
truncated clone was constructed by addition of an XbaI site
immediately downstream of NspI in the EcoRI -NspI fragment
and insertion of the resulting EcoRI -XbaI fragment into
EcoRI -XbaI digested pBXG1.
Transfections were performed as follows. K562 cells were
washed in serum-free RPMI 1640 media and 1.6 X 107 cells in
500 4d ofRPMI were added to a mixture of 3 lAg reporter plasmid,
30 ,tg transactivator plasmid (1:10 molar ratio), and 10 ,tg pTKO-
gal (Clontech) internal control plasmid. The final volume was
adjusted to 600 t,d with Phosphate Buffered Saline (PBS).
Electroporations were performed with a Bio-Rad Gene Pulser
set at 320 V and 960 /tF. After electroporation, the cells were
diluted into 10 ml RPMI plus 10% Fetal Bovine Serum (FBS)
in a 100 mM culture dish and incubated for 24 hours at 37°C
in 5% CO2. HeLa and HepG2 cells were transfected by the
calcium phosphate co-precipitation method (26). Each 60 mm
dish of cells (70% confluent) was transfected with the same
constructs as described above except that an SV40/CAT plasmid
(pCAT-Control; Promega) was used as an internal control.
Twenty four hours after transfection, K562, Hela and HepG2
cells were harvested and extracts were prepared in Promega
Reporter Lysis Buffer according to the manufacturer's
instructions. Luciferase activity was determined by the Promega
Luciferase Assay System, f-galactosidase was assayed as
described by Miller (31) and CAT activity was determined by
the CAT enzyme assay system (liquid scintillation modification)
according the manufactures instructions (Promega). Luciferase
activity was divided by j3-galactosidase activity or CAT activity
in each sample to control for different transfection efficiencies.
Results from GAL4 + HS2 (GAL4x2) 'y or tk/Luc co-
transfections in K562, Hela or HepG2 cells were set at 1 x and
results of other transfections in the same cell type were
normalized to this value. Experiments were performed at least
three separate times in triplicate; the results are the mean of all
experiments performed.
RESULTS AND DISCUSSION
Analysis of mutant HS 2 ( constructs in transgenic mice
The G to T mutation discussed above was originally analyzed
in constructs that were transfected into cultured erythroid cells.
To confirm the functional significance of the G to T transversion,
we analyzed the effects of this mutation on expression of a 5'
HS 2 3-globin construct in transgenic mice. Fertilized eggs were
injected with a wild-type construct, a construct containing a
deletion of the API-like sequences, a construct containing the
G to T mutation or a control construct containing an A to C
mutation as indicated in Figure 1. Embryos were removed at 16
days of gestation and fetal liver RNA was analyzed for correctly
initiated human f-globin mRNA by primer extension (data not
shown) and quantitated by solution hybridization (Figure 1). The
wild-type HS 2 ,3 construct was expressed at an average level
of 42% of the endogenous mouse (-globin gene per gene copy
and HS 2 AAP1 (was expressed at 2% of mouse (3-globin per
gene copy. These results are consistent with previous experiments
in transgenic mice. The G to T mutations decreased the level
of expression to 11% of mouse ,3-globin per gene copy. This
diminution of HS 2 enhancer activity confirms that the G residues
located 2 bp upstream of the consensus AP1 sites is required for
efficient 5' HS 2 activity. The A to C mutations did not affect
expression.
Isolation of LCR-F1 cDNA clone
To isolate proteins that bind to the APi-like sequences we
constructed a Xgtl 1 cDNA library with mRNA from K562 cells
and screened this unamplified library with multimerized copies
of the APi-like sites (24, 25). The criteria for identifying specific
clones were four-fold: (1) the fusion protein should bind to the
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Figure 1. Expression of 5' HS2 (3-globin gene constructs in transgenic mice.
The (3-globin locus on human chromosome 11 is illustrated at the top. Black boxes
represent individual globin genes, and arrows indicate DNase I hypersensitive
sites that flank the locus. The 5' HS 2 region is expanded to illustrate a 1.9 kb
KpnI-PvuII fragment that was inserted upstream of a 4.1 kb Hpal-XbaI fragment
containing the human ,B-globin gene. Restriction sites are as follows: K, KpnI;
H, HindIl; X, XbaI; Bg, BgII; P, PvuII. Duplicated API-like sites are indicated
by open boxes and an expanded view of this region is illustrated. Wild-type
sequence and mutations within and surrounding the APl-like sites are indicated
below the 5' HS 2 (K-P) fragment. Point mutations are marked by asterisks and
the dashed line in the AAP1 construct represents an 18 bp deletion. The fraction
of expressors represents the number of transgenic animals that express the
transgene. Expression/gene copy is the mean percent expression per gene copy;
this value is calculated as follows: (human (3 mRNA/human (3 gene copy)/(mouse
(3 mRNA/ mouse (3 gene copy) x 100. The data for 5' HS 2 (K-P) ( and 5' HS
2 (K-P) AAP1 b include data from Caterina et al. (21), and the data for the (3
alone construct are from Ryan et al. (9).
Competitor: vP 1 0 V
GST/LCR-F1: - + + + + +
1 2 3 4 5 6
Figure 2. Gel shift analysis of LCR-F1. Purified GST/LCR-FI fusion protein
was incubated with an end-labeled oligonucleotide containing the duplicated
APl-like sites from 5' HS 2 and a 100-fold molar excess of the indicated, unlabeled
oligonucleotides. Protein-DNA complexes were separated from free
oligonucleotides on 4% polyacrylamide gels.
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multimerized API-like sites, (2) it should not bind to a
multimerized C/EBP (CAAT/Enhancer Binding Protein) binding
site, (3) it should not bind efficiently to multimerized API-like
sites that contain the G to T mutation and (4) it should bind
efficiently to multimerized APi-like sites that contain the A to
C mutation. The single clone that met these criteria was plaque-
purified and designated LCR-F1. The 1.7 kb LCR-F1 insert was
subcloned into pGSTag (32) and the binding specificity of purified
GST/LCR-F1 fusion protein was determined by gel mobility shift
analysis (27, 28). As indicated in Figure 2, GST/LCR-F I bound
specifically to a 41 bp oligonucleotide containing the duplicated
APl sites (lane 2) and competition experiments (lanes 3-6)
confirmed the binding specificity described above.
LCR-F1 is a novel bZIP protein that contains a CNC domain
The nucleotide sequence of LCR-F1 is illustrated in Figure 3A.
The clone contains a nearly consensus Kozak sequence (33) that








M E V N T S A S E I L Y S A P P G D P L
otggaagtgaoacocatcagcaagtgaaatcctgtocagtgcccctcctggagacccactg
S T N Y S L A P N T P I N Q N V S L H Q
agcoccaactocagccttgcccccaacactcccatcaatcogaatgtcagcctgcatcag
A S L G G C S Q D F L L F S P E V E S L
gcgtccctggggggctgcagccaggacttcttactcttcagccccgaggtggaaagcctg
P V A S S S T L L P L A P S N S T S L N
cctgtggccagtagctccacgctgctcccgttggcccccagcaattctaccagcctcaac
S T F G S T N L T G L F F P P Q L N G T
tccaccttcggctccoccaacctgacagggctcttctttccoccccagcstcaatggcaca
A N D T A G P E L P D P L G G L L D E A
gccaatgocacagcaggcccagagctgcctgaccctttggggggtctgttagotgaagct
M L D E I S L M D L A I E E G F N P V Q
atgttggatgagatcagccttatggacctggccottgaogaaggctttaaccctgtgcog
A S Q L E E E F D S D S G L S L D S S H
gcctcccagctggaggaggaatttgoctctgactcaggcctttccttagactcgagccat
S P S S L S S S E G S S S S S S S S S S
agcccttcttccctoagcagctctgoaggcagttcttcctcttcttcctcctcctcttcc
S S S S A S S S A S S S F S E E G A V G
tcttcttcctctgcttcttcctctgcctcttcctccttttctgaggoaggtgcggttggc
Y S S D S E T L D L E E A E G A V G Y Q
tacagctctgactctgagaccctggatctggaagaggccgagggtgctgtgggctaccag
P E Y S K F C R M S Y Q D P A Q L S C L
cctgagtattccaagttctgccgcatgagctaccaggatccagctcagctctcotgcctg
P Y L E H V G H N H T Y N M A P S A L D
ccctocctggagcacgtgggccacaaccacocatacaocotggcocccagtgccctggoc
S A D L P P P S A L K K G S K E K Q A D
tcagccgacctgccaccacccagtgccctcoagaaaggcogcoaggagaagcaggctgoc
F L D K Q M S R D E H R A R A M K I P F
ttcctggacaogcagatgagccgggatgagcaccgagcccgagccatgaagatccctttc
T N D K I I N L P V E E F N E L L S K Y
accoatgacoaaatcatcaacctgcctgtggoggagttcoatgaactgctgtccaootac
Q L S E A Q L S L I R D I R R R G K N K
cagttgagtgaagcccagctgagcctcatccgagacatccggcgccggggcaogaacaag
M A A Q N C R K R K L D T I L N L E R D
atggcggcgcagaactgccgcaagcgcaagctggacaccatcctgaatctggagcgtgat
V E D L Q R D K A R L L R E K V E F L R
gtggaggacctgcagcgtgacaaagcccggctgctgcgggagaoagtggogttcctgcgc
S L R Q M K Q K V Q S L Y Q E V F G R L
tccctgcgacagatgaagcogaoggtccagagcctgtaccoggaggtgtttgggcggctg
R D E N G R P Y S P S Q Y A L Q Y A G D
cgagatgagaacggacgoccctactcgcccagtcagtatgcgctccagtacgccggggac
G S V L L I P R T M A D Q Q A R R Q E R
ggcagtgtcctcctcatcccccgcacgatggccgaccagcaggcccggcggcaggagagg
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11 1. I11 .:. 11:. . 11 :: 11 1 1 11 1:1 11 .1 1 I 1:1 1 11 111: 11 1I1 1 11 11 75% Identity
LCR-F1 RDEHRARAMKIPFTNDKIINLPVEEFNELLSKYQLSEAQLSLIRDIRRRGKNKMAAQNCRKRK
1: 1 11 111 .. I 1: I 11 1:: 1 .. I I. .*II . 1: 11 11 111: 1 1 1 I11 11 76% Identity
NF-E2 RDERRALAMKIPFPTDKIVNLPVDDFNELLAQYPLTESQLALVRDIRRRGKNKVAAQNCRKRK
Figure 3. Sequence of LCR-F1. Panel A. Combined sequence of 3 overlapping LCR-F1 cDNA clones. The predicted amino acid sequence of LCR-F1 is listed
above the DNA sequence. Panel B. Schematic of the LCR-F1 protein. The black boxes represent acidic, serine-rich and basic-leucine zipper domains of the protein.
Below the schematic the bZIP domain of LCR-F1 is expanded and compared to 5 other bZIP proteins. Open boxes designate consensus bZIP amino acids. CNC
is the Drosophila Cap N Collar protein (34) ; NF-E2 is a recently described erythroid-enriched factor that also binds to the 5' HS 2 API-like sites (30) ; cJun,
cFos and C/EBP homologies in this region have been described previously (50). Panel C. CNC domain. A 63 amino acid region of CNC, LCR-Fl and NF-E2
is compared. Lines represent identical amino acids; double dots represent conservative amino acid replacements; single dots represent semi-conservative amino acid
replacements. The CNC domain overlaps the basic region of these 3 proteins. Outside the CNC domain LCR-F1, NF-E2 and CNC diverge completely except for
limited homology in the leucine zipper region.
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conclusion was confirmed by the detection of 3 in frame stop
codons located 200 bp upstream of the Kozak sequence in an
overlapping cDNA clone isolated from another K562 library.
LCR-F1 has several striking features that are illustrated in Figure
3B. The carboxyl end of the protein contains a basic-leucine
zipper (bZIP) domain. Three leucine residues spaced 7 amino
acids apart are present at the amino terminal end of the zipper
region. The fourth and fifth hydrophobic amino acids in the zipper
are phenyalanine and methionine, and these are followed by 2
more leucine residues with correct spacing. Overall, the heptad
repeats of the zipper region consist of 7 hydrophobic amino acids.
A 6 amino acid linker separates the zipper and basic regions.
The basic region contains lysine and arginine residues at positions
identical to other bZIP proteins as well as the conserved
asparagine located 10 amino acids upstream of the linker.
Interestingly, LCR-F1 is 75% identical to the Drosophila Cap
N Collar [CNC; (34) ] protein and 76% identical to the erythroid-
enriched factor NF-E2 (30) in a 63 amino acid domain that
includes the basic region (Figure 3C). This extended basic region
may be involved in DNA binding and, if so, is analogous to the
POU domain located adjacent to POU-homeodomains in proteins
such as Pit-1, Oct-I and UNC 86 (35, 36). We propose to
designate this region the 'CNC domain'. Presumably LCR-F1,
NF-E2 and CNC are members of a larger family of proteins that
contain this newly recognized motif (30).
Located approximately 135 amino acids amino-terminal to the
CNC domain is a stretch of 40 amino acids that contains 30
serines (Fig 3). Within this region there is a patch of 14 serines
in succession. Few proteins contain a domain that is as rich in
serines. The serines may provide multiple sites for
phosphorylation and/or glycosylation that modify the structure
and/or activity of the protein. A 55 amino acid region adjacent
to the serine-rich domain of the protein is highly acidic (Figure
3). This domain has a net charge of -14. As described below,
the amino-terminal end of LCR-F I, which contains this acidic
region, functions as a strong transactivation domain specifically
in erythroid cells.
LCR-F1 is expressed in erythroid and non-erythroid cells
The Northern blot analysis illustrated in Figure 4A demonstrates
that the LCR-F1 cDNA hybridizes to 5.0 kb and 4.5 kb mRNAs
in K562, CEM-6 (T cell), NALM-6 (B cell), U937 (monocyte)
and Hela cells. Murine erythroleukemia (MEL) cells contain 5.0
kb and 4.3 kb LCR-Fl mRNAs. Human bone marrow (BM)
4~~~~~6~~~~ ~ ~ AJ
5.0 Kb
4.5 Kb ,I),
Figure 4. Northern blot analysis of LCR-Fl expression. Lanes 1-6 are 5 Ag
of total RNA from uninduced K562 (human erythroleukemia), CEM-6 (T cell),
NALM-6 (B cell), Hela (cervical carcinoma), U937 (monocyte), uninduced MEL
(murine erythroleukemia). Lanes 7 and 8 are 10 ,ug of total RNA from human
bone marrow and human reticulocytes, respectively. The blots were hybridized
with a randomly labeled 0.96 kb Bam]HlI-EcoRI fragment containing the 3' portion
of the cDNA. A 5' probe yielded identical results (data not shown).
contains both mRNAs but, interestingly, only the 4.5 kb mRNA
is observed in human reticulocytes (Figure 4B). We are presently
isolating cDNA clones for both mRNAs to determine whether
they encode distinct proteins.
Gal4/LCR-F1 fusion proteins activate high-level, erythroid-
specific globin gene expression
Initial attempts to over-express LCR-F1 in K562 cells did not
result in increased expression of a reporter construct composed
of 5' HS 2 sequences, a human -y-globin promoter, and a
luciferase gene (HS2-7y/luc; Figure SA). The level of HS 2-'y/luc
expression in these experiments was high without exogenous
LCR-F 1, presumably due to saturating levels of endogenous
LCR-F1. Background expression of the reporter gene was
decreased by deleting the duplicated AP1 sites in 5' HS 2 and
replacing them in their natural context with duplicated consensus
Gal4 binding sites (37) (Giniger et al. 1985; HS2(Gal4x2)--y/luc,
Figure 5). When the HS2(Gal4x2)-,y/luc construct was transfected
into K562 cells, expression was 39-fold lower than the wild-type
HS2(APlx2)-'y/luc construct (Fig SC). The LCR-Fl cDNA was
then inserted in frame into an expression plasmid (pBXG1, gift
of V. Seyfert and M. Ptashne) containing the Gal4 DNA binding
domain (Gal4 1-147) and co-transfected with HS2(Gal4x2)-'y/luc
into K562 cells. As illustrated in Figure SC, the Gal4/LCR-Fl
fusion protein enhanced HS2(Gal4x2)--y/luc expression 62-fold.
A mouse NF-E2 cDNA clone (30) was also inserted into pBXGl
and co-transfected with HS2(Gal4x2)-,y/luc into K562 cells. This
clone also enhanced reporter gene expression (8-fold). As
discussed below, both of these CNCbZIP proteins bind to the
duplicated API sites in HS2 and both may be involved in
activating human globin gene expression.
Co-transformations of Gal4/LCR-Fl and HS2(Gal4x2)--y/luc
were also performed in Hela and HepG2 cells to determine
whether transactivation was erythroid-specific. As indicated in
Figure SC, Gal4/LCR-Fl did not enhance expression in either
cell type; reporter gene expression was identical with Gal4 and
Gal4/LCR-FI plasmids. Gal4/NF-E2 was also tested in Hela and
HepG2 cells and like Gal4/LCR-FI this protein failed to enhance
expression. These results suggest that both LCR-F1 and NF-E2
transactivate reporter gene expression specifically in erythroid
cells. Gal4/VP-16 was co-transfected with HS2(Gal4x2)--y/luc
into Hela and HepG2 cells as a control. Reporter expression was
stimulated 5- and 8-fold, respectively; therefore, the -y-globin
gene promoter can be activated in these non-erythroid cell types.
Gal4/LCRF1 was also assayed for the ability to transactivate
a reporter gene containing a heterologous promoter. A
HS2(Gal4x2)-tk/luc reporter gene was co-transfected with
Gal4/LCRFI or with Gal4/NF-E2 in K562, Hela and HepG2
cells (Figure 6). Gal4/LCRF1 transactivated this reporter gene
107-fold and Gal4/NF-E2 transactivated the reporter 7-fold in
K562 cells. In Hela and HepG2 cells Gal4/LCRFI activated the
reporter only 3- and 12-fold, respectively; Gal4/NF-E2 activated
the reporter only 1- and 3-fold, respectively. Gal4/VP-16 was
co-transfected in Hela and HepG2 cells with HS2(Gal4x2)-tk/luc
as a control, and reporter gene expression was stimulated 98-
and 220-fold, respectively; this result demonstrates that the tk
promoter can be activated at a high level in these non-erythroid
cell types. The relatively low level of Gal4/LCRF I and Gal4/NF-
E2 transactivation in Hela and HepG2 cells confirms the
hypothesis that efficient transactivation by both of these proteins
is essentially erythroid-specific.
2388 Nucleic Acids Research, 1994, Vol. 22, No. 12
A.
REPORTERS
K H API X Bg Y Luc
Ilw_l
. -299 +37
HS2 (AP1 x2) '#Luc CAATGCG*GAG AGCTG
K H GaI4 X Bg Y Luc
I om- I I I I
-299 +37






















- + + + HS2 (Gal4x2) pLuc
Gal4
+ _ Gal41LCR-Fl
- - - + Gal4JNF-E2
Gal4NP-16
Figure S. LCR-F1 activates high level, human globin gene expression specifically in erythroid cells. Panel A. Reporter constructs used in transfections. HS2 (APlx2)
y/Luc contains wild-type 5' HS 2 sequences on a 1.5 kb KpnI-BglII fragment (see Figure 1); this fragment is inserted upstream of a human Ay globin promoter
that is linked to the luciferase gene. The duplicated API-like sites are boxed and an expanded view of this region is depicted below the fragment. HS2 (GAL4x2)
y/Luc contains the same 1.5 kb KpnI-BglII fragment as HS2 (APlx2) -y/Luc except that the duplicated API-like sites have been replaced by duplicated GAL4
binding sites; the duplicated GAL4 binding sites, which overlap by one base, are boxed. Panel B. Transactivators used in transfection experiments. The black box
designated GALA 1-147 represents the 147 amino acid DNA binding domain of the yeast GAL4 protein. The GALA construct contains only the GALA DNA binding
domain. GAL4/LCR-F1 is a fusion protein containing the GALA DNA binding domain fused to LCR-F1 and Gal4/NF-E2 is a fusion protein containing the GALA
DNA binding domain fused to NF-E2. GALA, GALA/LCR-F1 and Gal4/NF-E2 expression are driven by an SV40 early promoter and enhancer. Panel C. Results
of transfection experiments. The constructs listed below the graph and an internal control plasmid were transfected into K562, Hela and HepG2 cells and luciferase
activity was determined as described in Materials and Methods.
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LCR-F1 activation domain is an acidic region at the amino
terminus
Figure 7 illustrates results of initial experiments to map the
activation domain of LCR-F1. Deletion of the b/Zip region in
the Gal4/LCR-F1 fusion protein increased expression of the
reporter gene from 62-fold to 142-fold above expression of the
reporter gene alone. Surprisingly, deletion of the serine rich
region increased expression even further; reporter gene
expression in this case was 177-fold above background. Although
this result suggests that the serine domain is not required for
activity of the fusion protein, the serines may play an important
structural role in the native protein. Serine modification may alter
the structure of the native protein so that the powerful activation
domain can be positioned in a specific orientation to maximally
stimulate expression.
Deletion of the carboxyl terminal sequences of NF-E2 also
stimulated expression; this truncated protein enhanced expression
of HS2(Gal4x2)--y/luc 18-fold. A stretch of 52 amino acids in
this truncated protein contains a net negative charge of -12.
Therefore, both LCR-Fl and NF-E2 contain strong acidic
activating domains.
Gal4/VP-16 was also co-transfected into K562 cells with
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Figure 6. LCR-F1 transactivates a heterologous promoter specifically in erythroid cells. Panel A. Reporter constructs used in transfections. The reporters were identical
to the reporters illustrated in Figure 5 except that the tk promoter and 5' untranslated sequence (-120 to +20) replaced the -y-globin promoter and 5' untranslated
sequence (-299 to +37). Panel B. Results of transfection experiments. The constructs listed below the graph and an internal control plasmid were transfected into
K562, Hela and HepG2 cells and luciferase activity was determined as described in Materials and Methods.
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Gal4/NF-E2. The Gal4/VP-16 fusion protein transactivated the
reporter 167-fold. This is approximately the same level of
activation observed with Gal4/LCR-F1 and is somewhat higher
than the activity observed with GAL4/NF-E2.
Relationship between LCR-Fl and NF-E2
Andrews et al. (30) recently described the cloning of NF-E2 from
murine erythroleukemia (MEL) cells and Ney et al. (38)
subsequently reported the cloning and characterization of human
NF-E2. This protein is part of a heterodimeric complex which
also binds to the duplicated APi1 sites in 5' HS 2 in vitro. As
discussed above, NF-E2 and LCR-F1I are both bZIP proteins that
are 76% identical in a 63 amino acid CNC domain which includes
the basic region. Although the 2 proteins are highly homologous
in this region, they diverge outside the CNC domain except for
limited homology in the leucine zipper.
What is the relationship between NF-E2 and LCR-F 1 in
erythroid cells? The proteins may form heterodimers in vivo.
However, mimmunoprecipitations of erythroid nuclear extracts with
antiserum against NF-E2 reveal only NF-E2 (45 Kd) and a
smaller protein (18 Kd) (30, 38, 39) Alternatively, LCR-F1 and
NF-E2 may function at different developmental stages; 5' HS
2 activates globin gene expression in embryonic, fetal and adult
life (13, 40-43) and different protein complexes that bind to
the APi1-like sites may be involved in expression at these different
stages.
LCR-Fl and erythroid-specific globin gene expression
Although LCR-F 1 is not erythroid-specific, efficient
transactivation of human globin gene expression by this protein
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possible explanations for this observation. LCR-FlI may enhance
expression only after interacting with the erythroid-enriched
protein GATA-1 (44, 45) that binds approximately 50 bp
downstream of the API-like sites in 5' HS 2 (19). Alternatively,
LCR-Fl may enhance expression through an erythroid-specific
co-activator. An interesting precedence for this latter model has
recently been described. An interaction between the ubiquitous
transcription factor Oct-lI and a B lymphocyte specific co-activator
may be responsible for B-cell specific immunoglobulin gene
expression. This conclusion is supported by 2 pieces of data.
First, Oct-I plus a purified B-cell specific factor OCT-B
efficiently transcribe immunoglobulin genes in vitro (46)
secondly, immunoglobulin expression is not inhibited in mice
(47) or in cultured B cells (48) by a knock out mutation in the
Oct 2 gene. Although Oct 2 is B-cell-specific, the protein is not
required for B-cell-specific immunoglobulin gene expression.
After this work was completed, Chan and Kan (49) published
the sequence of NrfI (NF-E2 related factor 1) which is highly
homologous to LCR-Fl1. LCR-FlI and Nrfl cDNAs are identical
except that LCRFI1 contains a 91 bp insertion located 119 bp
upstream of the predicted translational start site. This insertion,
which is most likely an untranslated exon, produces an in frame
stop codon 241 bp upstream of the translational start site. The
LCR-F 1 open reading frame is 447 codons whereas Nrf1 is 760
codons. Southern blot hybridizations suggest that a single gene
encodes LCR-Fl1 and Nrfl1.
In summary, we have cloned and characterized a novel human
transcription factor (LCR-FI1) that binds to 03-globin LCR
sequences and strongly activates human globin gene expression.
LCR-Fl1 contains a 63 amino acid segment that has been
designated the CNC domain; this domain is greater than 70%
HS2 (GAL4X2) ylLuc
ACTIVATION In K562









Figure 7. Mapping the LCR-F1 transactivation domain. The GAL4, GAL4/LCR-FI and GAL4/NF-E2 transactivators and HS2(GALAx2)-y/Luc reporter were as
described in Figure 5. GAIA/LCR-FI (AbZIP) encodes a fusion protein with a truncation of the carboxyl-terminal 214 amino acids; this deletes the bZIP domain.
GAIA/LCR-FI (A~bZIP, SER) encodes a fusion protein with a truncation of the carboxyl-terminal 289 amino acids; this mutation deletes the bZIP and serine-rich
domains. GAL4/NF-E2 AbZIP encodes a fusion protein with a truncation of the carboxyl-terminal 198 amino acids; this mutation deletes the bZIP region. The
transactivator clones, which were driven by the SV40 promoter, the HS2 (GAL4x2) -y/Luc reporter and a tk/lacZ plamid were co-transfected into K562 and activity
was determined as described in the legend to Figure 5.
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identical in the Drosophila segmentation protein Cap N Collar
(34) , the erythroid-enriched protein NF-E2 (30) and LCR-Fl.
LCR-F1 is not erythroid-specific but activates globin gene
expression preferentially in erythroid cells. These results suggest
that LCR-Fl may interact with other proteins, perhaps erythroid-
specific co-activators, to direct high-level expression of human
e-, -y- and j3-globin genes.
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